<DOC>
	<DOCNO>NCT01258075</DOCNO>
	<brief_summary>Colesevelam oral suspension study treatment type 2 diabetes mellitus ( T2DM ) evaluate clinical safety efficacy patient age 10-17 year . The patient may treat Metformin antidiabetic drug treatment previous three month . Study Hypothesis : Colesevelam oral suspension pediatric subject T2DM safe , well tolerate , show improve blood sugar control ( evidenced significant change baseline hemoglobin A1C [ HbA1c ] ) .</brief_summary>
	<brief_title>Colesevelam Pediatric Type 2 Diabetes Mellitus Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus , define American Diabetes Association ; Understand study procedure agree participate give write assent obtain write consent parent legal guardian screening ; Males females age 10 17 year , inclusive , randomization ( randomization must occur 18th birthday ) ; HbA1c screen 7.0 % 10.0 % , inclusive ; Fasting Cpeptide &gt; 0.6 ng/mL ; Antidiabetic treatment screening : Treatmentna√Øve untreated ; OR On metformin monotherapy : Metformin monotherapy initiate prior screening . Fasting plasma glucose &gt; 270 mg/dL ; Diagnosis type 1 diabetes ; History one episode ketoacidosis initial diagnosis type 2 diabetes mellitus ; Positive autoimmune marker ; Creatinine clearance &lt; 70 mL/min ; Alanine transaminase aspartate aminotransferase elevation &gt; 2.5 X upper limit normal ; Participation another interventional research study protocol past 60 day ; Female subject lactating , pregnant , plan become pregnant within 1 year screening ; Female subject sexually active unwilling use appropriate contraception duration study ; History bowel obstruction ; Other significant organ system illness condition ( include psychiatric developmental disorder ) , opinion Investigator , would prevent full participation ; Triglycerides &gt; 500 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>blood glucose</keyword>
	<keyword>anti-diabetic</keyword>
	<keyword>bile acid sequestrant</keyword>
	<keyword>colesevelam HCl</keyword>
	<keyword>oral suspension</keyword>
	<keyword>pediatric</keyword>
	<keyword>add-on therapy</keyword>
	<keyword>add-on metformin</keyword>
	<keyword>metformin</keyword>
	<keyword>adolescent</keyword>
	<keyword>lipid</keyword>
</DOC>